Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | CMO | November 28, 2022 | December 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date November 28, 2022 · Filed December 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,184,037 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Grant · Acquired 16,927 · Balance 2,184,037 F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2032-11-28 | Direct | 2,315,439 |
Reported balance
After 2022-11-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-28 · Grant · Acquired 2,315,439 · Balance 2,315,439 F2: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 782,408 |
Reported balance
Holding disclosure · report date 2022-11-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 782,408 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
F2: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 66,666 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 19 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 66,666 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option grant vests every four months beginning September 7, 2019. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 250,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 18 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2028-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 17 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 97,009 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 16 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,009 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 75,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 15 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 7,123 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 14 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,123 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 1,200,000 | $3.26 | $3,912,480.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 9 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,557,718 F2 · price: This transaction was executed in multiple trades at prices ranging from $3.16 to $3.37. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 93,750 | $0.39 | $36,562.50 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 8 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,757,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 750,000 | $0.39 | $288,750.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 7 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,663,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 66,666 | $0.52 | $34,666.32 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 6 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,913,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 250,000 | $0.57 | $141,250.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 5 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,847,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment to Form 4 filed on May 5, 2020 amends the transaction code to "M" from the original and incorrect transaction code of "P." The transaction corresponds with the nonqualified option exercise on line 5 in Table II. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 100,000 | $0.49 | $49,000.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 4 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 97,009 | $0.56 | $54,325.04 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 3 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,497,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 75,000 | $0.57 | $42,750.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 7,123 | $0.61 | $4,345.03 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-029995 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: 750,000 options vest immediately upon grant and 500,000 options vest upon the achievement of certain additional strategic milestones specified in the award agreement. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025311 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments over the one year period commencing on January 7, 2020. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 21:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-023648 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-09-12 Read SEC document |
| August 09, 2019 Filed Sep 1, 2020 17:46 UTC | CytoDyn Inc. CYDY · Entity 5856 | GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000015 · primary_doc.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Custodian for daughter Disclosed balance after: 97,980 F1 · shares: This transaction involved a gift of securities by the reporting person to his daughter, who shares the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 09, 2019 Filed Sep 1, 2020 17:46 UTC | CytoDyn Inc. CYDY · Entity 5856 | GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000015 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,491,052 F1 · shares: This transaction involved a gift of securities by the reporting person to his daughter, who shares the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-19-017510 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments, commencing on September 1, 2019. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 22:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionWarrant (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000899243-19-017092 · doc4.xml · derivative · entry 8 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 22:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrant (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0000899243-19-017092 · doc4.xml · derivative · entry 7 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2021-05-26 F1 · price: On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 22:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrant (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0000899243-19-017092 · doc4.xml · derivative · entry 6 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-05-26 F1 · price: On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 22:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-017092 · doc4.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,170 F1 · price: On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 22:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 50,000 | $0.40 | $20,000.00 |
DisclosureSEC source: 0000899243-19-017092 · doc4.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 23:28 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0000899243-19-004306 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-02-16 F1 · derivative.exercise_date: The warrant will vest in four equal quarterly installments commencing on May 16, 2019. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 166,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 11 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires 2021-02-10 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 10 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-05-26 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 250,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 9 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2028-11-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 8 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F4 · derivative.exercise_date: The options vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 97,009 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 7 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,009 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 6 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 7,123 | Not disclosed Strike: $0.61 | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · derivative · entry 5 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,123 shares Expires 2027-04-10 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 22,980 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · nonDerivative · entry 4 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As Custodian for Daughter; See Footnote Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 23,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · nonDerivative · entry 3 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As Custodian for Daughter; See Footnote Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 691,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:39 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 1,243,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029194 · doc4.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 166,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 11 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 166,666 Underlying: Common Stock · 166,666 shares Expires 2021-02-10 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 10 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2021-05-26 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 250,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 9 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-11-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 8 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F4 · derivative.exercise_date: The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 97,009 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 7 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,009 Underlying: Common Stock · 97,009 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 6 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 7,123 | Not disclosed Strike: $0.61 | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · derivative · entry 5 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,123 Underlying: Common Stock · 7,123 shares Expires 2027-04-10 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 22,980 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · nonDerivative · entry 4 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As Custodian for Daughter; See Footnote Disclosed balance after: 22,980 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 23,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · nonDerivative · entry 3 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As Custodian for Daughter; See Footnote Disclosed balance after: 23,180 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 691,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 691,208 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 1,243,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029259 · doc4.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243,170 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 21:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-18-028721 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-11-08 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.